Calendario›COGT›CGT9486

CGT9486

CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors

Ensayo de Cogent Biosciences, Inc. en Gastrointestinal Stromal Tumors (del registro, en inglés).

Fase

Fase 1/2

Estado

Completado

Participantes

51

previstos

Centros

6

Fin del objetivo primario

may 2020

fecha real

Qué significa cada fase y cada estado.

Estudio de intervención, no aleatorizado, abierto. Comenzó en mar 2015.

Qué mide

Part 1: Recommended Phase 2 Dose (RP2D) of CGT9486 (Cycle 1 of Part 1 (Cycle length = 28 days)) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including gastrointestinal stromal tumor (GIST). CGT9486 (fka PLX9486) is designed to block KIT gene mutations. These mutations can cause cancer and cancer cell growth. By blocking these mutations, the drug may kill the cancer cells with the mutation and/or stop the tumor from growing. By combining CGT9486 (fka PLX9486) with PLX3397 and CGT9486 (fka PLX9486) with sunitinib, the investigators hope to block most KIT gene mutations that drive cancer growth.

Más ensayos de COGT

Todos los de COGT, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT02401815), actualizada en ene 2025.